All In Biotech

Drug Trial Radar · NCT06542237

Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males

Open Label Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Daily Oral Dosing of YCT-529 for 28 Days, 90 Days or 180 Days in Healthy Men

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Sep 11, 2024

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Lead sponsor
YourChoice Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 28 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2a open-label, dose escalation 3 part-study, 28-day, 90-day or 180 day repeat dose study of YCT-529 in healthy males who have decided to have a vasectomy and are waiting for the procedure and for men who have decided not to father children in the future. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and to assess sexual function and mood.

Conditions

  • Male Contraception

Interventions

  • YCT-529Drug

    In Part 1, 4 dosing cohorts and one optional 5th cohort with 4 participants each will be evaluated. In Part 2, up to 5 dosing cohorts and 2 optional cohorts with 4 participants each will be evaluated. Dose levels will be selected based on doses that were deemed safe and well tolerated upon 28-day administration in Part 1 and any previous Part 2 cohorts. In Part 3, 3 dosing cohorts and one optional 4th cohort with 10 participants each will receive doses within the range of doses that were deemed safe and well tolerated in Part 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and nature of any adverse events, dose-limiting adverse events and serious adverse adverse events.Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  2. Vital signs assessment (heart rate)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  3. Vital signs assessment (blood pressure)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  4. Vital signs assessment (oral temperature)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  5. 12-lead ECG assessment (heart rate)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  6. 12-lead ECG assessment (QT interval)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  7. 12-lead ECG assessment (QTcF Interval)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  8. 12-lead ECG assessment (PR Interval)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  9. 12-lead ECG assessment (QRS Duration)Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  10. Clinical laboratory assessment- Hemoglobin Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  11. Clinical laboratory assessment- Hematocrit Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  12. Clinical laboratory assessment- Packed Cell Volume Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  13. Clinical laboratory assessment- Red Blood Cell Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  14. Clinical laboratory assessment- Mean Corpuscular Volume Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  15. Clinical laboratory assessment- Mean Corpuscular Hemoglobin Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  16. Clinical laboratory assessment- Mean Corpuscular Hemoglobin Concentration Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  17. Clinical laboratory assessment- Platelet Count Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  18. Clinical laboratory assessment- White Blood Cell Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  19. Clinical laboratory assessment- Neutrophil Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  20. Clinical laboratory assessment- Lymphocyte Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  21. Clinical laboratory assessment- Monocyte Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  22. Clinical laboratory assessment- Eosinophil Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  23. Clinical laboratory assessment- Basophil Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  24. Clinical laboratory assessment- Coagulation Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  25. Clinical laboratory assessment- Activated Partial Thromboplastin Time Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  26. Clinical laboratory assessment- Fibrinogen Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  27. Clinical laboratory assessment -Sodium Blood Sample TestsTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  28. Clinical laboratory assessment- Chloride Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  29. Clinical laboratory assessment- Potassium Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  30. Clinical laboratory assessment- Bicarbonate Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  31. Clinical laboratory assessment- Urea Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  32. Clinical laboratory assessment -Creatinine Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  33. Clinical laboratory assessment -Bilirubin (total) Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  34. Clinical laboratory assessment -Bilirubin (direct) Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  35. Clinical laboratory assessment -Alkaline Phosphatase Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  36. Clinical laboratory assessment -Aspartate aminotransferase Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  37. Clinical laboratory assessment -Alanine aminotransferase Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  38. Clinical laboratory assessment -Lactate dehydrogenase Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  39. Clinical laboratory assessment -Creatinine Kinase Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  40. Clinical laboratory assessment - Gamma glutamyl transferase Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  41. Clinical laboratory assessment - Troponin Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  42. Clinical laboratory assessment - Total Protein Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  43. Clinical laboratory assessment - Albumin Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  44. Clinical laboratory assessment - Calcium Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  45. Clinical laboratory assessment - Fasting Glucose Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  46. Clinical laboratory assessment - Non Fasting Glucose Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  47. Clinical laboratory assessment - Fasting Triglycerides Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  48. Clinical laboratory assessment - Total Fasting Cholesterol Blood Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  49. Clinical laboratory assessment-Bilirubin Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  50. Clinical laboratory assessment-Urobilinogen Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  51. Clinical laboratory assessment- Ketones Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  52. Clinical laboratory assessment- Glucose Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  53. Clinical laboratory assessment- Protein Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  54. Clinical laboratory assessment- Blood Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  55. Clinical laboratory assessment- Nitrites Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  56. Clinical laboratory assessment- pH Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  57. Clinical laboratory assessment- Specific Gravity Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  58. Clinical laboratory assessment- Leukocytes Urine Sample TestTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.
  59. Clinical laboratory assessment- High Sensitivity C- Reactive ProteinTime frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research (NZCR)

    Grafton, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.